Asthma has been recognized as a chronic, complicated condition that requires a mix of treatments. Interindividual heterogeneity in clinical reactions to various medications, on the other hand, complicated asthma therapy. A tailored approach to asthma therapy identified appropriate responders to certain drugs or those who are more likely to encounter adverse reactions. Pharmacogenetic investigations of genes in the leukotriene, glucocorticoid, and beta2-adrenergic receptor pathways had enhanced the understanding of how gene variation influences treatment responses to several types of anti-asthma medicines. Previously, such research was restricted to retrospective assessments of potential genes in the leukotriene, glucocorticoid, and beta2-adrenergic receptor pathways in the clinical trial populations. Prospective genotype-stratified trials in asthma, on the other hand, had just been completed, and new genome-wide association studies had found additional pharmacogenetic loci.
Future pharmacogenetic research had continued to focus on genome-wide techniques and the discovery of new therapeutic pathways, therefore, the replication of prior genotypic correlations in large clinical trial populations was concluded to be crucial. The relevance of genetic indicators in predicting the clinical responses to certain medications was highlighted in the overview of pharmacogenetics in asthma, which underlined the contributions of genomics research to the future of personalized therapy in asthma.